iBio, Inc. (IBIO) — research page

US · us-cm-kg/NASDAQ/IBIO · as of 2026-11-08

Identity and listing

The issuer is iBio, Inc., listed on NASDAQ under ticker IBIO, with ISIN US4510337086 and LEI 529900EW4RXUITGKUT34. Its security type is Corporate and its sector is 2834 Pharmaceutical Preparations. Its jurisdiction is United States, Delaware. The segment is not on the record. The issuer is listed and not halted.

The disclosure read

The record holds 86 filings in the twelve months from 2025-11-08 to 2026-11-08, across 45 filing days. The median gap between filing days is 5.5 days. The latest filing is dated 2026-10-19, 20 days before the record date, and is of type director_change. The exchange median is 52 filings, a median cadence gap of 6.0 days and a median latency of 5.0 days. The sector median is 63.0 filings, a median cadence gap of 6.0 days and a median latency of 4.0 days.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor of record is GRASSI & Co., CPAs, P.C., located in Jericho, New York. The record holds no auditor changes.

Events and halts

The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed, not halted.

Orderability

The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

The issuer's investor-relations page names 10 research houses: B Riley Securities, Brookline Capital Markets, Chardan Capital Markets, H.C. Wainwright, Jones Trading, Leerink Partners, LifeSci Capital, Lucid Capital Markets, Oppenheimer and Raymond James.

Open research

No openly published research notes were found on the record.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The record is sealed for the issuer in the years 2021, 2022, 2023, 2024, 2025 and 2026. The earliest sealed date for the market is 2021-01-04. The live record began on 2026-09-12.

Sources

10 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001420720.json (identity.jurisdiction)

10.4

https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)

10.5

https://mcp.us-cm-kg.ai/events/NASDAQ/IBIO (the disclosure lines)

10.6

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.7

https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/ibio-20260731x10k.htm (the auditor)

10.8

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.9

https://ir.ibioinc.com/stock-data/analyst-coverage (coverage)

10.10

https://mcp.us-cm-kg.ai/record/NASDAQ/IBIO (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"US4510337086"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:e7bd6d5ecbdad186.